Last reviewed · How we verify
Tryparsone — Competitive Intelligence Brief
unknown
Other
Live · refreshed every 30 min
Target snapshot
Tryparsone (tryparsamide). Tryparsone works by inhibiting the enzyme dihydrofolate reductase, which is essential for the survival of the trypanosome parasite.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Tryparsone TARGET | tryparsamide | unknown |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Tryparsone CI watch — RSS
- Tryparsone CI watch — Atom
- Tryparsone CI watch — JSON
- Tryparsone alone — RSS
Cite this brief
Drug Landscape (2026). Tryparsone — Competitive Intelligence Brief. https://druglandscape.com/ci/tryparsamide. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing